skip to content


Issue No. 50 | November 30, 2012

News and Features

December 1 is World AIDS Day

On December 1, AIDSinfo will join individuals and organizations across the globe in observing World AIDS Day 2012. The day is an occasion to consider how progress in HIV prevention, treatment, and research is bringing the world closer to the promise of an AIDS-free generation: 

  • According to estimates from the Centers for Disease Control and Prevention (CDC), prevention efforts have averted more than 350,000 HIV infections in the United States (a conservative estimate for the period of 1991 to 2006).
  • 31 Food and Drug Administration (FDA)-approved antiretroviral drugs are helping people with HIV live healthier, longer lives.
  • Research is underway to better understand HIV and how it causes disease, find new tools to prevent HIV infection, develop new and more effective treatments for people infected with HIV, and hopefully, find a cure.

Visit our World AIDS Day webpage [en español] to learn more about this annual observance and about advances in HIV treatment and research.

AIDSinfo and infoSIDA Respond to Changing Demand for Services

AIDSinfo is committed to meeting user needs and continually monitors the demand for products and services offered by AIDSinfo and infoSIDA. Based on current demand trends, AIDSinfo is implementing the following changes effective Monday, December 3, 2012.

Adjustment to call center services

  • Live one-on-one phone assistance in English and Spanish from health information specialists will be available Monday through Friday from 1 p.m. to 4 p.m. ET. Callers requesting help outside this time may leave a voicemail message with a call back number, and an information specialist will respond within two business days.
  • The Live Chat service in English and Spanish will be discontinued.

Adjustment in e-newsletter publication schedule

  • AIDSinfo will begin to publish its e-newsletter, At-a-Glance, every other week.
  • The Spanish e-newsletter, al instante, will be published once a month.
  • As necessary, AIDSinfo and infoSIDA will publish additional e-newsletters to announce breaking news, such as important advances in HIV treatment or the release of updated medical practice guidelines.

These changes will allow for expansion of AIDSinfo and infoSIDA products and services that are in demand, including further development of mobile-optimized content and applications and greater use of social media to connect with our users.

Please send any comments or questions regarding these changes to

Recent News from NIH, CDC, and FDA

NIH, CDC, and FDA recently announced the following news:

  • November 28, 2012: HIV Treatment Reduces Risk of Malaria Recurrence in Children

    “A combination of anti-HIV drugs has been found to also reduce the risk of recurrent malaria by nearly half among HIV-positive children, according to researchers supported by the National Institutes of Health.”

    For more information, read the NIH press release.  
  • November 27, 2012: More Than Half of Young HIV-Infected Americans Are Not Aware of Their Status

    “Young people between the ages of 13 and 24 represent more than a quarter of new HIV infections each year (26 percent) and most of these youth living with HIV (60 percent) are unaware they are infected, according to a Vital Signs report from the Centers for Disease Control and Prevention.  The most-affected young people are young gay and bisexual men and African-Americans, the report says.”

    For more information, read the CDC press release.
  • November 26, 2012: Draft Guidance on Vaginal Microbicides for the Prevention of HIV Infection

    “The FDA is announcing the release of a recently published Draft Guidance for Industry: Vaginal Microbicides: Development for the Prevention of HIV Infection

    “This draft guidance is intended to provide FDA's current thinking regarding development of vaginal microbicides for the prevention of human immunodeficiency virus (HIV) infection. Vaginal microbicides are products which may reduce HIV acquisition in women.”

    For more information, read the FDA press release.